MDMA-assisted dialectical behavioral therapy for borderline personality disorder: A qualitative study of mental health clinicians
Journal of Psychedelic Studies February 5, 2024 Ann M. Inouye, Aaron Wolfgang, Lianne T. Philhower 1 citation
In 2021, phase 3 clinical trials of MDMA-assisted therapy for treatment-resistant PTSD found that 71.2% of full-dose participants no longer met PTSD criteria. Although MDMA-assisted therapy is not FDA-approved for borderline personality disorder, its beneficial effects might be applicable. An exploratory, qualitative, interview-based study examined clinicians' perspectives by interviewing two dialectical behavioral therapy clinicians and two MDMA-assisted therapy clinicians. The study assessed underlying therapeutic mechanisms, pharmacological factors, and treatment context to improve clinical responses. Participants' codes revealed a chronological narrative with three treatment phases.